Ani Pharmaceuticals (ANIP) EBIAT (2016 - 2025)
Ani Pharmaceuticals (ANIP) has disclosed EBIAT for 16 consecutive years, with $27.5 million as the latest value for Q4 2025.
- Quarterly EBIAT rose 367.52% to $27.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $78.3 million through Dec 2025, up 522.94% year-over-year, with the annual reading at $78.3 million for FY2025, 522.94% up from the prior year.
- EBIAT hit $27.5 million in Q4 2025 for Ani Pharmaceuticals, up from $26.6 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of $27.5 million in Q4 2025 to a low of -$24.2 million in Q3 2024.
- Historically, EBIAT has averaged -$595250.0 across 5 years, with a median of -$1.1 million in 2021.
- Biggest five-year swings in EBIAT: crashed 23506.98% in 2022 and later surged 1165.25% in 2024.
- Year by year, EBIAT stood at -$24.1 million in 2021, then soared by 82.42% to -$4.2 million in 2022, then soared by 127.22% to $1.2 million in 2023, then plummeted by 989.7% to -$10.3 million in 2024, then skyrocketed by 367.52% to $27.5 million in 2025.
- Business Quant data shows EBIAT for ANIP at $27.5 million in Q4 2025, $26.6 million in Q3 2025, and $8.5 million in Q2 2025.